NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Evox Therapeutics

Evox Therapeutics

Private
OxfordHealthcare & Life Scienceshttps://www.evoxtherapeutics.com/

Last Round

Series C

Feb 18, 2021

Total Funding Raised

$168.25M

Company Overview

Evox Therapeutics is a biotechnology company that develops exosome-based therapeutics for the treatment of severe rare, neurological, and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

exosome therapeuticsdrug delivery platformgene editingextracellular vesiclestargeted drug deliverybiotech platformrare disease therapyexosome engineeringblood-brain barrierbiopharma partnershipexosome techdelivery vehicletherapeutic payloaddrug delivery techbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Evox Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Evox Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Evox Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 18, 2021
Convertible DebtJun 9, 2020
GrantMar 22, 2019
GrantNov 13, 2018
GrantOct 1, 2018
Series B
Sep 3, 2018

Evox Therapeutics Investors

Notable investors and investment history

Evox Therapeutics investors
InvestorRounds
Redmile GroupSeries B, Series C
Innovate UKGrant
UK governmentGrant
GVSeries B, Series C
Cowen Private InvestmentsSeries B, Series C
Duchenne UKGrant
Oxford Science EnterprisesSeries B, Series C, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 3, 2018

    $45M round led by Redmile Group

Evox Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Evox Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Evox Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range40
Year Founded2016
Last FundingFeb 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.